Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level650 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06431100 | a Single-arm, Single-center, Open Clinical Study(GK-01) | recruiting | — | 10 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06426654 | Sintilimab Combined With LDRT for Neoadjuvant Treatment of Locally Advanced dMMR/MSI-H Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 45 | West China HospitalOTHER | 0 | May 23, 2024 |
| NCT06421220 | Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer | not yet recruiting | N/A | 484 | Qilu Hospital of Shandong UniversityOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05494086 | Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer | recruiting | N/A | 300 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT04878783 | Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG | active not recruiting | — | 138 | University of Roma La SapienzaOTHER | 2 | May 9, 2024 | clinicaltrials |
| NCT06389448 | Comparison of pCLE and EB in Gastric Lesion Diagnosis | recruiting | N/A | 366 | Huazhong University of Science and TechnologyOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT02931890 | Multicentric Randomised Trial for Resectable Gastric Cancer(CRITICS-II) | active not recruiting | Phase 2 | 207 | The Netherlands Cancer InstituteOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06384300 | Financial Incentives and Motivational Intervention to Improve Gastric Cancer Screening in China | not yet recruiting | N/A | 5,000 | Peking UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06374901 | Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. | not yet recruiting | Phase 2 | 134 | Xiangdong ChengOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06371586 | Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC | recruiting | Phase 2 | 67 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04547725 | Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal Carcinomatosis(CRS-IP) | recruiting | N/A | 48 | National Taiwan University HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05714124 | Liver Embolization Approaches for Tumor Management(LEATUM) | recruiting | — | 580 | IRCCS San RaffaeleOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06349967 | Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer | not yet recruiting | Phase 2 | 59 | West China HospitalOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06341595 | Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04660760 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 116 | Academic and Community Cancer Research UnitedOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06339216 | A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT06335576 | Establishment of Serum Proteomics Subtypes of Gastric Cancer and Its Clinical Application | not yet recruiting | — | 89 | Shanghai Zhongshan HospitalOTHER | 0 | Mar 28, 2024 | clinicaltrials |
| NCT06310473 | Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | not yet recruiting | Phase 2 | 30 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05975749 | Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer | recruiting | Phase 2 | 114 | Fudan UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04597294 | Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence(CHIMERA) | recruiting | Phase 3 | 600 | Jagiellonian UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06295094 | The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.(EPICURE) | not yet recruiting | Phase 2 | 264 | Odense University HospitalOTHER | 5 | Mar 6, 2024 | clinicaltrials |
| NCT06275204 | H. Pylori Screen-and-treat Study in a Population of Young Adults | recruiting | — | 6,800 | University of LatviaOTHER | 6 | Mar 5, 2024 | clinicaltrials |
| NCT06283121 | A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer | not yet recruiting | Phase 2 | 30 | China Medical University, ChinaOTHER | 0 | Feb 29, 2024 | clinicaltrials |
| NCT01935778 | Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH | recruiting | Phase 3 | 286 | Asan Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03950271 | SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 25 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06242613 | National Multicenter Cohort Study of Robot-Assisted Gastrectomy Versus Laparoscopy in Gastric Cancer(ROBOTAG) | enrolling by invitation | — | 400 | Hospital Universitario de Gran Canaria Doctor NegrínOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06238167 | Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC | not yet recruiting | Phase 2 | 40 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Feb 2, 2024 | clinicaltrials |
| NCT06229197 | Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric Cancer | not yet recruiting | N/A | 176 | Sichuan UniversityOTHER | 0 | Jan 29, 2024 | clinicaltrials |
| NCT05918094 | Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06213519 | HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis | not yet recruiting | Phase 2 | 69 | Sichuan UniversityOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT05140746 | Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer | recruiting | N/A | 40 | Ruijin HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | recruiting | Phase 2 / Phase 3 | 286 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 2 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT05561504 | Helicobacter Pylori Local Prevalence and Antibiotic Resistance(HelicoPTER) | recruiting | — | 20,000 | Technical University of MunichOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT01678027 | Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication | active not recruiting | Phase 3 | 1,838 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121700 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G) | recruiting | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05494060 | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma(EXPLORING) | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06115629 | Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial(SARONG-II) | not yet recruiting | Phase 3 | 952 | University of Dublin, Trinity CollegeOTHER | 5 | Nov 3, 2023 | clinicaltrials |
| NCT06102759 | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102772 | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102785 | Fruquintinib Combined With TAS102 for Advanced Gastric Cancer | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05551416 | The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer | recruiting | — | 1,200 | EDUARDO ALBENIZOTHER | 1 | Oct 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2024source: clinicaltrials